A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)
This study is a randomized, positive parallel controlled, multicentre phase III clinical trial to evaluate the efficacy and safety of TQB2450 combined with anlotinib versus paclitaxel for injection (albumin bound) in subjects with advanced triple negative breast cancer.
Triple Negative Breast Cancer
DRUG: TQB2450|DRUG: Anlotinib|DRUG: Paclitaxel for Injection (albumin bound)
Progression free survival (PFS) evaluated by Independent Review Committee(IRC), PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause, based on IRC., up to 96 weeks
Overall response rate (ORR), Percentage of participants achieving complete response (CR) and partial response (PR)., up to 96 weeks|Disease control rate（DCR）, Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD)., up to 96 weeks|Duration of Response (DOR), DOR defined as time from earliest date of disease response to earliest date of disease progression based on radiographic assessment., up to 96 weeks
This study is a randomized, positive parallel controlled, multicentre phase III clinical trial to evaluate the efficacy and safety of TQB2450 combined with anlotinib versus paclitaxel for injection (albumin bound) in subjects with advanced triple negative breast cancer.